Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical development company focused on neuroscience programs targeting neurologic and neuropsychiatric disorders. The company holds exclusive rights in the U.S., Canada, and Mexico for two primary drug candidates: Ketamir-2 (an oral ketamine analog for neuropathic pain and depression) and MIRA-55 (a novel oral pharmaceutical marijuana analog for cognitive function). The reporting period covers the fiscal year ended December 31, 2024.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(7.85) million | $(11.98) million |
| Operating Expenses | $8.02 million | $8.53 million |
| Research & Development (R&D) | $3.31 million | $1.57 million |
| General & Administrative (G&A) | $4.71 million | $6.50 million |
| Cash Used in Operating Activities | $(5.56) million | $(4.53) million |
| Cash Provided by Financing Activities | $3.79 million | $8.78 million |
| Cash and Cash Equivalents (Ending) | $2.83 million | $4.60 million |
| Accumulated Deficit | $(29.14) million | $(21.29) million |
| Debt | $0 (Related party notes paid in full) | $0 (Related party notes paid in full) |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $4.1 million (34%) compared to 2023, primarily due to a reduction in G&A expenses and the absence of significant non-cash interest expenses related to the write-off of deferred financing costs in 2023.
- R&D Increase: R&D expenses increased by $1.74 million (111%) driven by IND-enabling studies, toxicology assessments, and consultant fees for Ketamir-2.
- G&A Decrease: G&A expenses decreased by $1.79 million (28%) due to reduced personnel costs and a concerted effort to conserve cash.
- Related Party Travel: Related party travel costs of $0.45 million incurred in 2023 were eliminated in 2024 following the termination of an aircraft lease in March 2023.
- Financing Activity: The company raised approximately $3.6 million in net proceeds from an At-The-Market (ATM) offering in 2024, compared to $7.7 million from the IPO and related activities in 2023.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Going Concern: The filing contains a "Going Concern" warning. The company has no revenue, an accumulated deficit of $29.1 million, and insufficient cash to fund operations for the next 12 months. Management expects current cash to last through the third quarter of 2025.
- Capital Needs: The company plans to secure additional capital through public/private equity offerings or strategic transactions. There is no assurance that funding will be available on acceptable terms.
- Acquisition: On March 19, 2025, MIRA entered into a binding Letter of Intent (LOI) to acquire SKNY Pharmaceuticals, Inc. via a stock exchange. SKNY holds rights to SKNY-1 (weight loss/smoking cessation) and will provide a $5 million capital infusion. Completion is contingent on valuation and shareholder approval.
- Executive Compensation: In March 2025, the CEO's salary was increased to $485,000, and a new Executive Incentive Compensation Plan (EICP) was adopted with bonuses tied to clinical milestones, partnerships, and capital raises.
Risks and Contingencies
- Regulatory Approval: Ketamir-2 is awaiting FDA clearance for a neurotoxicity study before U.S. human dosing can proceed. Phase I trials are planned for Israel in Q1 2025.
- Liquidity: Failure to raise additional capital may require the company to curtail operations or delay clinical trials.
- Intellectual Property: The company relies on licenses from related parties (MIRALOGX) for Ketamir-2 and has no issued patents for MIRA-55.
- Geopolitical: Clinical trials planned in Israel face potential disruption due to geopolitical tensions.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to raise capital before Q3 2025 to avoid operational curtailment.
- SKNY Acquisition: Monitor the progress of the SKNY Pharmaceuticals acquisition, specifically the independent valuation and the $5 million capital infusion.
- Regulatory Status: Confirm the completion of the FDA-requested neurotoxicity study for Ketamir-2 and the initiation of Phase I trials in Israel.
- Related Party Transactions: Review the terms of the MIRALOGX license agreement and the potential conflicts of interest given the shared founder/largest shareholder.
- ATM Offering: Track the utilization of the $75 million ATM shelf registration to assess dilution and funding success.